Takis’ Post

The IgG antibody, shaped like the letter Y. It is made up of four polypeptide chains: two identical light chains and two identical heavy chains. Generally speaking, the closer the light chain and heavy chain pair are to the natural conformation, the better the specificity of the antibody. The stronger the ability of the antibody to bind to the antigen, the higher the efficacy of the antibody drug. But this is not entirely correct. Higher affinity can indeed lead to better drug efficacy. High affinity can increase the residence time of the drug at the target, potentially improving the therapeutic effect. It is not a simple linear relationship. Ultra-high affinity may cause "binding site barriers" and hinder the penetration of antibodies in tumor tissues. Sometimes antibodies with medium affinity may perform better in terms of in vivo distribution and permeability. Scientific development requires a lot of trial and error. I hope I can contribute a little bit in this process. If you encounter any problems in your antibody discovery process, please do not hesitate to contact our Cusabio Technology LLC technical team for consultation. 😎

🔬 🧫 🧬 Don’t miss out on an exclusive roundtable discussion on "Developing Therapies that Target Multiple Immune Pathways" at the Antibody Therapeutics Xchange - Brussels! 🗓 18 Nov 2024 | 09:05 - 10:05 CET 📍 Bi/Multispecifics Track Key topics include: ✅ Optimal design for a multispecific TCE - what have we learned, and what’s next? ✅ Improving tumor selectivity - do we need new combinations of TAAs? ✅ Checkpoint inhibition - address it in the same molecule or separately? 🔑 Led by Leonard Wossnig, CTO at LabGenius an expert in AI, quantum machine learning, and computational drug design. 💡 Secure your FREE spot! https://lnkd.in/eQWzNrAH Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #BiSpecifics #Multispecifics #CancerResearch #Immunotherapy #AIInHealthcare #LabGenius #DrugDiscovery #PrecisionMedicine #ImmunePathways #TCellEngagers #CheckpointInhibition #Oncology #Pharma #Biotech #HealthcareInnovation #Xchange2024 #PharmaTech #Biopharma #Brussels2024 #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

The traditional linear and sequential model of #DrugDevelopment poses many challenges in immunotherapy and targeted therapy including, but not limited to, lengthy timelines and high costs. However, as Ravi Karra highlights in this piece, advanced imaging modalities such as MRIs and digital biomarkers offer a valuable way to overcome these challenges. These technologies are particularly unique because they allow for early detection of treatment response and identification of predictive biomarkers by identifying functional and molecular information. The future of #LifeSciences depends on innovative technology such as this. It's always great to see how leaders are investing in new ways to research and develop life-changing drugs. #DigitalTransformation #Innovation #Research

Will you be joining Biogen, QurAlis, AbbVie & more at the 3rd ALS Drug Development Summit this May? Your early bird discount expires tomorrow - register here https://ter.li/72fo3u before midnight Friday 5th to save $700 Presentation highlights include: 🧠 Characterising NfL changes up to 10 years prior to ALS diagnosis with Neta Zach, Takeda 🧠 Employing iPSC-derived motor neurones to model diverse forms of ALS with Wen-Hsuan (Wen) Chang, AcuraStem 🧠 Investigating transcriptomic aberrations in ALS patients with C9orf72 hexanucleotide repeat expansion with Tao Yang, Prevail Therapeutics 🧠 Streamlining Efficiency of QRL-201 with Generative AI Technology with Emma Bowden, QurAlis 🧠 Exploring the potential of combination therapy & showcasing latest progress of PrimeC with Shiran Zimri, NeuroSense Therapeutics 🧠 Targeting SOD1 with CRISPR-based gene editing to diminish mutant SOD1 & restore motor neuronal function with Shih-Ching Joyce Lo, Biogen View all this and more in the 2024 agenda: https://ter.li/gvrgmo

You might hear the term "human Fc monoclonal antibody" in biotechnology industry. Let’s talk about what it means and why it is so important. 👇 🧪 A monoclonal antibody is a type of protein that's engineered in the lab to bind to specific targets in the body. The "Fc" portion refers to the fragment crystallizable region, which is crucial for the antibody's interaction with the immune system. When you hear "human Fc," it means that this part of the antibody is designed to be compatible with the human immune system, making it safer and more effective for use in medical diagnostics and treatments. ✅ 🔥𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫? These antibodies play a pivotal role in medical research and diagnostics. They enable highly precise targeting, which can lead to more accurate tests, better understanding of diseases, and the development of new therapies. In diagnostics, human Fc monoclonal antibodies are essential for detecting biomarkers that signal the presence of specific diseases, enabling earlier and more accurate diagnosis. ❤️ At Bcell Design, we are dedicated to advancing this critical technology. Our work in designing, producing, and marketing human Fc monoclonal antibodies is at the forefront of transforming diagnostics and bringing innovative solutions to healthcare providers worldwide. Want to learn more about how these antibodies are revolutionizing diagnostics? Stay tuned for more insights, and let’s connect! 😉 #monoclonalantibodies #mabs #diagnosticsexcellence #IVD #invitrodiagnostic

#nanoparticles #standards ⬇Download our latest #WhitePaper to learn everything you need to know about "Smart Nanoparticles" (NPs): https://okt.to/Hcu6Wa A new generation of smart NPs has emerged, capable not only of improving drug solubility and bioavailability but also of responding to internal and external cues such as biomarkers, pH, temperature and light to achieve specific disease targeting. This white paper considers ☑ expert opinions, drug approvals, and clinical trials that illustrate the progress and potential of these technologies. ☑ We also explore the power of artificial intelligence to guide development of these technologies and ☑ acknowledge the challenges associated with their use, including toxicology and scale up barriers. #nanoparticles #DrugDelievery #ScienceForaSaferWorld

How is this novel? The use of non-proteinogenic amino acids has had many precedents, in both 'wet' and computational discovery approaches. (edit) I not necessarily like raining on others' parades, but: 1. Such things (false claims of novelty) deprive prior innovators of credit; 2. Lead potential investors, lured by the hype of disruptive "innovation", into an elevated risk of losses, when the company commits patent infringement, or burns investors' money and then finds it impossible to protect some generated "novel" IP due to the existence of prior art. In the specific context of generative, in silico design, refer, for example, to the section: "Beyond the 20 naturally occurring amino acids" in "What has de novo protein design taught us about protein folding and biophysics?" by David Baker https://lnkd.in/gzKHhDyn Yes, the Baker group has been doing it for years. I can show examples of successful generative design too, the earliest from 20 years (!) ago (ricin toxin inhibitors). Or refer to my patent US8361969B2, granted in 2013 (CD4 mimetics, cyclic, freely mixing L- ,D- and other). Or to the title of my 2010 NSF award #1013428 ("De Novo Design of Unnatural Peptides - Affordable Drug Discovery Platform"). New researchers and new tools are very welcome in any discipline, and this one is not an exception. But please remember that there are some standards of conduct.

💡Biotech's most innovative in 2024 were announced by Fast Company this week and as ever there is a great blend of technology. Here's the Top 10 below 👇 1️⃣ Insilico Medicine - focusing on drug-disease targets. 2️⃣ ElevateBio - Catching genetic disorders at the root. 3️⃣ Personalis, Inc. - Deetecting cancers early. 4️⃣ Exscientia - AI to personalize cancer treatments. 5️⃣ Rocket Pharmaceuticals - Targeting rare diseases with gene therapy. 6️⃣ Guardant Health - Cancer detection and drug development. 7️⃣ Inato - Bringing clinical trials to local hospitals. 8️⃣ Elucidata - Cleaning up messy biomedical data. 9️⃣ Maravai LifeSciences - Improving the safety of immunotherapy. 🔟 Emerald Cloud Lab - Providing 24/7 lab services in the cloud. 🧑🔬 Its great to see companies receive recognition for hard work especially given the different stages they are on. Nice to see Personalis and Guardant represent the #LiquidBiopsy market too 🩸! #fcmostinnovative #biotech

Fusion Antibodies PLC (AIM:FAB), CEO Adrian Kinkaid presented at the Proactive One2One Investor Conference. The company is diversifying its focus from primarily #therapeutics to include diagnostics and research applications of #antibodies. Kinkaid emphasised the company's expertise in #antibody discovery, engineering, and manufacturing, highlighting its ability to reduce production costs and enhance efficiency. Key to Fusion Antibodies' strategy are two innovative platforms: 'OptiMAL' and AI/ML (Artificial Intelligence/Machine Learning) based antibody design. 'OptiMAL' offers a highly diverse library of sequences based on the human immune repertoire, providing intact IgG molecules and mammalian cell expression, promising a more reliable manufacturing route. Meanwhile, their AI/ML initiative collaborates with partners and Oxford University to theoretically design antibodies, significantly improving efficiency and specificity in antibody development. 2023 was a challenging year for #FusionAntibodies due to its reliance on VC-funded #biotech companies. However, the company has made decisions to reduce costs and position itself for a rebound as market conditions improve. Their expanded focus includes #immunodiagnostics and veterinary medicine, aiming to diversify revenue streams and reduce dependency on the volatile biotech sector. Kinkaid concluded by noting Fusion Antibodies' readiness to collaborate on antibody development and optimisation, underscoring their commitment to innovation and market expansion. This proactive approach in antibody technology and strategic diversification positions Fusion Antibodies as a forward-thinking player in the biotech industry. Watch at #Proactive #ProactiveInvestors #AIM #FAB https://ow.ly/urnF50QrCQu

New biotech startup emerges to introduce new class of biologic drugs Flagship Pioneering has unveiled Abiologics, a new company pioneering supranatural biologics. With an initial $50 million commitment, Abiologics aims to develop Synteins™, a novel class of programmable medicines that could advance patient treatment across various diseases, initially focusing on oncology and immunology. Synteins™ represent a paradigm shift in biologic design. Unlike traditional biologics limited to 20 natural amino acids, Synteins are computationally designed using a broader set of artificial building blocks, including D-amino acids. This approach leverages cutting-edge generative AI for design and innovative chemical synthesis techniques for production. The result is a class of biotherapeutics with extraordinary properties: ✔ Immune evasion: By using non-natural building blocks, Synteins can potentially avoid recognition by the immune system. ✔ Enhanced stability: This could lead to less frequent dosing and possibly oral delivery options. ✔ Improved tissue penetration: Synteins may access previously unreachable parts of the body. ✔ Programmability: These molecules can be designed to interact with virtually any therapeutic target. This news appeared today on BioPharmaTrend.com. Follow Where Tech Meets Bio (Substack Newsletter) for daily biotech insights with a focus on platforms and technological advances. #biopharmatrend #drugdiscovery #biotech Image source: Distinctive Roles of D-Amino Acids in the Homochiral World: Chirality of Amino Acids Modulates Mammalian Physiology and Pathology, Jumpei Sasabe and Masataka Suzuki, The Keio Journal of Medicine 68(1)